Osteosarcoma News and Research

RSS
Between two and three percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with approximately 1,200 new cases diagnosed in the United States each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group (COG), the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.
2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

Researchers evaluate the dual-therapeutic effect of gene therapy in mouse model of osteosarcoma

Researchers evaluate the dual-therapeutic effect of gene therapy in mouse model of osteosarcoma

Research develops unique delivery system to treat osteosarcoma

Research develops unique delivery system to treat osteosarcoma

Using unsupervised machine learning algorithms to classify osteosarcoma

Using unsupervised machine learning algorithms to classify osteosarcoma

Upgraded tumor model points the way toward more effective cancer therapies

Upgraded tumor model points the way toward more effective cancer therapies

Newly identified bone matrix protein may help treat osteosarcoma

Newly identified bone matrix protein may help treat osteosarcoma

Study reveals the LDLR pathway as a ubiquitous metabolic vulnerability in high grade gliomas

Study reveals the LDLR pathway as a ubiquitous metabolic vulnerability in high grade gliomas

Simple blood tests for telomeric protein could provide a valuable screen for certain cancers

Simple blood tests for telomeric protein could provide a valuable screen for certain cancers

World Cancer Day 2023: Perspectives from The Institute of Cancer Therapeutics

World Cancer Day 2023: Perspectives from The Institute of Cancer Therapeutics

The role of exosomes in osteosarcoma diagnosis, prognosis, and therapeutics

The role of exosomes in osteosarcoma diagnosis, prognosis, and therapeutics

Treating the cerebrospinal fluid to protect the brain from chemotherapy's toxic effects

Treating the cerebrospinal fluid to protect the brain from chemotherapy's toxic effects

Research identifies unique vulnerabilities in ALT cancers that can serve as novel therapeutic targets

Research identifies unique vulnerabilities in ALT cancers that can serve as novel therapeutic targets

Inhaled recombinant IL-15 tested in pet dogs with metastatic lung disease from osteosarcoma or melanoma

Inhaled recombinant IL-15 tested in pet dogs with metastatic lung disease from osteosarcoma or melanoma

Scientists identify the role of phospholipid in maintaining epithelial cellular adhesion

Scientists identify the role of phospholipid in maintaining epithelial cellular adhesion

Soy molasses and kudzu roots may help fight against pediatric tumors

Soy molasses and kudzu roots may help fight against pediatric tumors

TTUHSC researcher secures $1.9 million grant to investigate vulnerabilities in ALT cancers

TTUHSC researcher secures $1.9 million grant to investigate vulnerabilities in ALT cancers

Study links phthalates to higher incidence of specific childhood cancers

Study links phthalates to higher incidence of specific childhood cancers

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Penn Medicine receives $12.3 million NIH grant to study FLASH radiotherapy for cancer

Penn Medicine receives $12.3 million NIH grant to study FLASH radiotherapy for cancer

Antibody combination produces a synergistic response in difficult-to-treat pediatric cancers

Antibody combination produces a synergistic response in difficult-to-treat pediatric cancers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.